



**Lothar Kanz**

**Kontakt**

Lothar Kanz

## Publikationen (13)

Bilich T, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper J, Klein R, Kohlbacher O, Kanz L, Rammensee H, Stevanovic S, Brümmendorf T, Schemionek M, Rieth J, Nelde A, Bichmann L, Roerden M, Salih H, Kowalewski D, Schuster H, Tsou C, Marcu A, Neidert M, Lübke M, Walz J. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. *Blood* 2018; 133:550-565.

Kampa-Schittenhelm K, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm M. Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBF $\beta$ -MYH11 leukemia. *Oncotarget* 2018; 9:11876-11882.

Backert L, Stevanovic S, Rammensee H, Weisel K, Kohlbacher O, Salih H, Kanz L, Niederwieser D, Vucinic V, Brümmendorf T, Schemionek M, Neidert M, Berlin C, Schuster H, Walz S, Kowalewski D, Walz J. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens. *Oncotarget* 2017; 8:43915-43924.

Kampa-Schittenhelm K, Salitzky O, Akmut F, Illing B, Kanz L, Salih H, Schittenhelm M. Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns. *BMC cancer* 2016; 16:25.

Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Häring H, Weisel K. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. *Ann Hematol* 2011; 91:729-735.

Borchmann P, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause S, Mueller R, Fuchs M, Rank A, Greil R, Haverkamp H, Diehl V, Cerny T, Markova J, Ho A, Eich H, Mueller-Hermelink H, Kanz L, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. *J Clin Oncol* 2011; 29:4234-42.

Thiel E, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Leithäuser M, Mergenthaler H, Hundsberger T, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. *Lancet Oncol* 2010; 11:1036-47.

Schittenhelm M, Bokemeyer C, Wong K, Corless C, Kanz L, Störkel S, Kurek R, Honecker F, Morich J, Harlow A, Oechsle K, Kollmannsberger C, Heinrich M. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. *Mol Cancer Ther* 2009; 8:481-9.

Horger M, Pereira P, Claussen C, Kanz L, Vonthein R, Denecke B, Driessen C. Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. *Br J Radiol* 2008; 81:386-96.

Hartmann J, Grünwald V, Kanz L, Käfer G, Pintoffl J, Meisinger I, Huober J, Horger M, Schleicher J, Mayer F, German sarcoma group. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). *Cancer* 2007; 110:861-6.

Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen C, Driessen C. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. *Cancer* 2007; 109:1617-26.

Scheding S, Bergmann M, Shimosaka A, Wolff P, Driessen C, Rathke G, Jaschonek K, Brugger W, Kanz L. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. *Transfusion* 2002; 42:321-7.

Lang K, Huber S, Lang F, Fritz J, Kanz L, Scheel-Walter H, Schittenhelm M, Myssina S, Roll B, Wieder T. Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency. *Cell Physiol Biochem* 2002; 12:365-72.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)